Dipnarine Maharaj, MB, CHB, MD, FRCP
Basic profileDipnarine Maharaj is an Oncology physician affiliated with Maharaj Institute of Immune Regenerative Medicine. OpenAlex indexes 57 publications with 2,027 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10301 Hagen Ranch Rd
Suite # 600
Boynton Beach, FL 334373724
Telephone
561-752-5522Registry record last updated 8 Jul 2007.
Clinical trials
- A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Sponsor: Dipnarine Maharaj
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%BCL-2 Inhibitor100%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Low-Toxicity Natural Killer Cell-Based Immunotherapy for NRAS-Driven Mucosal Melanoma: Advances in Immune Regenerative Medicine
Critical Reviews in Immunology
2025 - Personalized Precision Immunotherapy for Amyotrophic Lateral Sclerosis (ALS)
Critical Reviews in Immunology
2023 - Successes and Challenges in Taming the Beast: Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis
Critical Reviews in Immunology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”